Recent News
A Cancer Vaccine Could Potentially Help Mesothelioma Patients
Researchers are looking at a vaccine to maintain patient health after cancer treatment, which could be effective for mesothelioma in the future. The vaccine is specifically made for each patient…
Researchers are Targeting Fibrosis to Improve Mesothelioma Care
Researchers have found that targeting lung fibrosis can help people with mesothelioma. People with mesothelioma usually suffer from fibrosis, which is the stiffening of tissue surrounding tumors. Certain drugs to…
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
Primary Outcome Measures Dose-limiting Toxicity [ Time Frame: First 21 days of treatment. ] The incidence of DLTs during the DLT assessment period. Frequency and Severity of Adverse Events (AE) [ Time Frame: Screening to 90 days…
OT-101 Useful for COVID-19 and Cancers Like Mesothelioma
Researchers are looking at a new treatment for mesothelioma. It is a multimodal treatment (multiple treatments combined) consisting of the immunotherapy drug Keytruda and a new drug called OT-101. OT-101…
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Primary Outcome Measures Phase 1: [ Time Frame: 28 days ] To determine the MTD and dosing schedule of TNG908 Phase 2: [ Time Frame: 16 weeks ] To assess anti-neoplastic activity of TNG908 in patients with MTAP-deleted…
Prehab and Rehab for Mesothelioma
Mesothelioma is a rare and deadly cancer of the mesothelium, which is a membrane that surrounds multiple organs including the lungs and abdomen. The best thing for patients after a…
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Primary Outcome Measures Safety and tolerability of IK-930 [ Time Frame: Through study completion, an average of 36 months ] The frequency and severity, incidence of treatment-emergent and treatment-related adverse events using NCI-CTCAE v5.0…
A Gene Therapy Could Improve Survival for Mesothelioma
Results from a new study involving a genetic therapy for pleural mesothelioma have been submitted at the University of Leicester. Researchers at the United Kingdom university designed a treatment to…
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Primary Outcome Measures Phase 1: Number of Patients who Experience Dose-Limiting Toxicity [ Time Frame: 21 days ] Phase 1/1B: Number of patients who experience a treatment-related adverse event [ Time Frame: Up to 2 years ] Phase…
Tremelimumab and Durvalumab Combination Can Improve Mesothelioma Survival
Studies show that durvalumab and tremelimumab work very well together while treating mesothelioma. A phase I clinical trial was performed at the Baylor College of Medicine in conjunction with Baylor…
